004370:KRXNongshim Co., Ltd. Analysis
Data as of 2026-06-12 - not real-time
₩377,500.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Nongshim trades well below its discounted cash‑flow estimate, suggesting a sizable upside potential. The forward P/E sits in a modest range, indicating the stock is priced on a value basis rather than growth hype. Technical signals are mixed: RSI hovers around the midpoint, while MACD remains in a bearish configuration, and volume has been tapering, pointing to a neutral short‑term bias. However, the price is comfortably above the recent support level and still has room before hitting the identified resistance, offering a cushion for upside moves. The company’s low beta underscores limited market‑wide volatility, yet the 30‑day price swing is relatively high, reflecting sector‑specific price swings. Dividend yield is modest but the payout ratio is well below 30%, supporting sustainability. Fundamentally, revenue growth is positive, margins are stable, and cash generation comfortably exceeds debt obligations.
Given the combination of undervaluation, solid cash flow, and defensive consumer positioning, the stock appears attractive for investors seeking value with a dividend component. While macro‑economic headwinds could affect consumer spending, the diversified product portfolio and global footprint provide resilience. The current market sentiment is extremely bullish, as indicated by the fear‑greed index, which may have pushed the price down relative to intrinsic value. Overall, the fundamentals and valuation metrics align for a buy stance across horizons, with the caveat of monitoring short‑term technical momentum.
Given the combination of undervaluation, solid cash flow, and defensive consumer positioning, the stock appears attractive for investors seeking value with a dividend component. While macro‑economic headwinds could affect consumer spending, the diversified product portfolio and global footprint provide resilience. The current market sentiment is extremely bullish, as indicated by the fear‑greed index, which may have pushed the price down relative to intrinsic value. Overall, the fundamentals and valuation metrics align for a buy stance across horizons, with the caveat of monitoring short‑term technical momentum.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price near support with room to upside
- Bearish MACD but neutral RSI suggests limited downside
- Low beta reduces market‑wide shock risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF valuation indicates substantial upside
- Stable cash flow and low debt‑to‑equity ratio
- Defensive consumer‑staples sector supports earnings stability
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Sustainable dividend payout with healthy cash generation
- Global diversification mitigates single‑market exposure
- Potential macro‑economic volatility could temper growth
Key Metrics & Analysis
Financial Health
Revenue Growth4.60%
Profit Margin5.02%
P/E Ratio11.1
ROE6.35%
ROA3.18%
Debt/Equity6.10
Op. Cash Flow₩322.5B
Free Cash Flow₩165.6B
Technical Analysis
TrendNeutral
RSI48.1
Support₩353,500.00
Resistance₩410,000.00
MA 20₩385,175.00
MA 50₩379,040.00
MA 200₩412,707.50
MACDBearish
VolumeDecreasing
Fear & Greed Index88.84
Valuation
Fair Value₩614,208.53
Target Price₩504,263.16
Upside/Downside33.58%
GradeUndervalued
TypeValue
Dividend Yield1.60%
Risk Assessment
Beta0.33
Volatility33.30%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.